10x Genomics, Inc. (TXG) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TXG SEC filings page.
10x Genomics, Inc. (TXG) reported $616.9M in revenue over the twelve months to Jun 30, 2026, down 4.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash generation turned positive as 2025’s operating loss narrowed sharply, revealing a business needing far less reinvestment than before.
Cash conversion changed the funding profile: operating cash flow rose from$6.7M in FY2024 to$136.1M in FY2025. Operating cash flow converted almost fully into free cash flow because capital spending was only$5.9M , showing that the improvement was not just an accounting recovery.
Operating margin improved from
Liquidity is structurally ample: the current ratio was 4.5x and debt-to-equity was 0.3x in FY2025, leaving liabilities modest relative to equity. Yet retained earnings remained negative at
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of 10x Genomics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
10x Genomics, Inc. held $523.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $136.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and 10x Genomics, Inc. scores 86/100 among other emerging companies.
10x Genomics, Inc. had 128M shares outstanding at the end of fiscal year 2025, against 122M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and 10x Genomics, Inc. scores 60/100 among other emerging companies.
10x Genomics, Inc. spent $238.6M on research and development in fiscal year 2025, which was 33.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and 10x Genomics, Inc. scores 66/100 among other emerging companies.
10x Genomics, Inc. reported revenue of $642.8M in fiscal year 2025, against $610.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and 10x Genomics, Inc. scores 46/100 among other emerging companies.
10x Genomics, Inc.'s operations generated $136.1M of cash in fiscal year 2025, against $6.7M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and 10x Genomics, Inc. scores 100/100 among other emerging companies.
10x Genomics, Inc.'s cash, cash equivalents and investments came to $523.4M at the end of fiscal year 2025, against $245.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and 10x Genomics, Inc. scores 75/100 among other emerging companies.
10x Genomics, Inc. scores 24.73, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($10.5B) relative to total liabilities ($245.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
10x Genomics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
10x Genomics, Inc. reported a net loss of $43.5M while generating $136.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
10x Genomics, Inc. generated $151.0M in revenue in Q2 2026. This represents a decrease of 12.6% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.
10x Genomics, Inc.'s EBITDA was -$9.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 126.1% from the same quarter a year earlier. Against the prior quarter it is down 39.5%.
10x Genomics, Inc. reported -$17.9M in net income in Q2 2026. This represents a decrease of 151.9% from the same quarter a year earlier. Against the prior quarter it is down 33.1%.
10x Genomics, Inc. earned -$0.14 per diluted share (EPS) in Q2 2026. This represents a decrease of 150.0% from the same quarter a year earlier. Against the prior quarter it is down 40.0%.
Cash & Balance Sheet
10x Genomics, Inc. generated $15.4M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 4.6% from the same quarter a year earlier. Against the prior quarter it is down 37.3%.
10x Genomics, Inc. held $502.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
10x Genomics, Inc.'s gross margin was 74.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.1 percentage points.
10x Genomics, Inc.'s operating margin was -13.0% in Q2 2026, reflecting core business profitability. This is down 30.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
10x Genomics, Inc.'s net profit margin was -11.9% in Q2 2026, showing the share of revenue converted to profit. This is down 31.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.9 percentage points.
10x Genomics, Inc.'s ROE was -2.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 6.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.
Capital Allocation
10x Genomics, Inc. invested $56.8M in research and development in Q2 2026. This represents a decrease of 7.2% from the same quarter a year earlier. Against the prior quarter it is down 0.1%.
10x Genomics, Inc. invested $1.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 0.6% from the same quarter a year earlier. Against the prior quarter it is down 0.6%.
Not reported for Q2 2026.
TXG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $151.0M-12.6% | $150.8M-2.6% | $166.0M+0.6% | $149.0M-1.7% | $172.9M+12.9% | $154.9M+9.8% | $165.0M-10.3% | $151.7M-1.3% |
| Cost of Revenue | $38.5M-19.4% | $44.7M-9.7% | $53.0M-2.0% | $48.7M+7.6% | $47.8M-2.2% | $49.4M+2.8% | $54.1M-20.7% | $45.3M-22.1% |
| Gross Profit | $112.5M-10.1% | $106.2M+0.7% | $113.0M+1.9% | $100.3M-5.7% | $125.1M+20.0% | $105.4M+13.5% | $111.0M-4.2% | $106.4M+11.4% |
| R&D Expenses | $56.8M-7.2% | $56.8M-11.5% | $56.0M-16.4% | $57.2M-13.6% | $61.2M-2.7% | $64.2M-6.4% | $67.0M+2.6% | $66.2M-0.5% |
| SG&A Expenses | $78.7M+5.7% | $66.4M-26.0% | $76.6M-18.3% | $75.4M-7.8% | $74.4M-10.4% | $89.7M+4.6% | $93.8M+8.9% | $81.7M-0.9% |
| Operating Income | -$19.6M-164.9% | -$17.0M+56.7% | -$19.5M+60.8% | -$32.2M+22.3% | $30.1M+172.2% | -$39.3M+36.0% | -$49.8M+9.7% | -$41.5M+56.2% |
| EBITDA | -$9.9M-126.1% | -$7.1M+77.4% | -$9.5M+76.9% | -$21.9M+32.5% | $37.9M+215.8% | -$31.3M+40.1% | -$41.1M+9.6% | -$32.5M+61.9% |
| Interest Expense | $0-100.0% | N/A | $0 | -$3K-250.0% | $3K+200.0% | $0-100.0% | $0-100.0% | $2K+100.0% |
| Income Tax | -$714K-129.0% | $623K-26.9% | $1.1M+63.4% | -$733K-155.7% | $2.5M+200.6% | $852K-60.3% | $648K-72.5% | $1.3M+5.9% |
| Net Income | -$17.9M-151.9% | -$13.5M+60.8% | -$16.2M+66.9% | -$27.5M+23.2% | $34.5M+191.1% | -$34.4M+42.7% | -$49.0M-0.1% | -$35.8M+61.6% |
| EPS (Basic) | -$0.14-150.0% | -$0.10+64.3% | -$0.13+68.3% | -$0.22+26.7% | $0.28+187.5% | -$0.28+44.0% | -$0.410.0% | -$0.30+62.0% |
| EPS (Diluted) | -$0.14-150.0% | -$0.10+64.3% | -$0.13+68.3% | -$0.22+26.7% | $0.28+187.5% | -$0.28+44.0% | -$0.410.0% | -$0.30+62.0% |
| Diluted Shares (Avg) | 130M+4.4% | 128M+4.6% | N/A | 126M+4.0% | 125M+3.7% | 123M+2.7% | N/A | 121M+2.6% |
TXG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B+5.1% | $1.0B+12.4% | $1.0B+13.4% | $1.0B+9.6% | $980.0M+5.4% | $903.4M-2.1% | $918.6M-4.8% | $937.8M-1.1% |
| Current Assets | $674.7M+2.9% | $669.7M+15.5% | $684.5M+17.1% | $659.8M+11.1% | $655.7M+13.2% | $579.7M+2.2% | $584.4M-2.0% | $593.9M+5.6% |
| Cash & Equivalents | $502.5M+26.4% | $490.3M+30.0% | $474.0M+37.8% | $432.7M+8.7% | $397.7M+4.7% | $377.1M+6.0% | $344.1M-4.2% | $398.2M+26.5% |
| Short-Term Investments | $49.5M-0.1% | $49.6M-0.6% | $49.4M+0.2% | $49.6M | $49.5M+18319.7% | $49.8M+210.9% | $49.3M+67.7% | $0-100.0% |
| Inventory | $52.6M-23.7% | $53.5M-28.4% | $56.3M-32.2% | $62.0M-34.1% | $69.0M-21.9% | $74.7M-10.2% | $83.1M+12.8% | $94.0M+16.2% |
| Accounts Receivable | $47.5M-4.9% | $39.0M-25.7% | $47.0M-46.5% | $43.8M-47.6% | $50.0M-45.2% | $52.5M-42.4% | $87.9M-23.5% | $83.5M-19.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $6.9M+53.4% | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% |
| Total Liabilities | $204.5M-1.1% | $201.4M+2.5% | $245.0M+17.5% | $242.2M+12.7% | $206.7M+0.5% | $196.5M-3.7% | $208.5M-7.0% | $215.0M+5.7% |
| Current Liabilities | $118.5M+5.6% | $113.6M+5.3% | $153.5M+30.5% | $147.3M+21.5% | $112.2M+1.1% | $107.9M-0.8% | $117.6M-7.5% | $121.2M+15.8% |
| Non-Current Liabilities | $86.0M-9.0% | $87.8M-0.9% | $91.6M+0.8% | $94.9M+1.2% | $94.5M-0.1% | $88.6M-7.1% | $90.9M-6.3% | $93.8M-4.9% |
| Total Equity | $825.5M+6.8% | $814.3M+15.2% | $796.3M+12.1% | $785.1M+8.6% | $773.3M+6.8% | $706.9M-1.7% | $710.1M-4.2% | $722.8M-3.0% |
| Retained Earnings | -$1.5B-5.1% | -$1.5B-1.5% | -$1.5B-3.0% | -$1.5B-5.4% | -$1.5B-6.1% | -$1.5B-11.7% | -$1.5B-14.2% | -$1.4B-14.8% |
Not reported in any period shown, so not listed: Long-Term Debt.
TXG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.0M-4.1% | $26.1M-24.0% | $40.8M+704.3% | $43.2M+99.7% | $17.7M+136.2% | $34.4M+318.4% | -$6.7M-126.2% | $21.6M+185.5% |
| Depreciation & Amortization | $9.7M+23.7% | $10.0M+24.1% | $10.1M+15.0% | $10.3M+14.9% | $7.8M-12.9% | $8.0M-12.7% | $8.8M-10.0% | $9.0M-4.4% |
| Stock-Based Compensation | $25.6M-6.0% | $22.6M-27.1% | N/A | $25.3M-25.5% | $27.2M-29.2% | $31.1M-14.0% | N/A | $33.9M-15.7% |
| Capital Expenditures | $1.6M+0.6% | $1.6M-15.6% | $1.8M-34.6% | $687K-82.3% | $1.6M-45.2% | $1.9M-34.9% | $2.7M-21.3% | $3.9M-74.5% |
| Free Cash Flow | $15.4M-4.6% | $24.5M-24.4% | $39.0M+512.1% | $42.5M+139.6% | $16.1M+249.3% | $32.5M+274.2% | -$9.5M-142.4% | $17.8M+143.8% |
| Investing Cash Flow | -$7.7M-723.7% | -$1.3M+30.7% | -$1.8M+96.5% | -$8.8M-143.3% | -$939K-107.9% | -$1.9M-117.8% | -$51.6M-493.9% | -$3.6M-173.8% |
| Financing Cash Flow | $3.0M-14.4% | -$8.4M-2094.5% | $2.2M-50.4% | $617K+295.5% | $3.5M-23.5% | $422K-74.2% | $4.5M-19.5% | $156K-96.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TXG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.5%+2.1pp | 70.4%+2.3pp | 68.1%+0.8pp | 67.3%-2.8pp | 72.3%+4.3pp | 68.1%+2.2pp | 67.2%+4.3pp | 70.2%+8.0pp |
| Operating Margin | -13.0%-30.4pp | -11.3%+14.1pp | -11.8%+18.4pp | -21.6%+5.7pp | 17.4%+44.7pp | -25.4%+18.2pp | -30.2%-0.2pp | -27.4%+34.3pp |
| Net Margin | -11.9%-31.8pp | -8.9%+13.3pp | -9.8%+19.9pp | -18.4%+5.1pp | 20.0%+44.7pp | -22.2%+20.3pp | -29.7%-3.1pp | -23.6%+36.9pp |
| Return on Equity | -2.2%-6.6pp | -1.7%+3.2pp | -2.0%+4.9pp | -3.5%+1.4pp | 4.5%+9.7pp | -4.9%+3.5pp | -6.9%-0.3pp | -5.0%+7.5pp |
| Return on Assets | -1.7%-5.3pp | -1.3%+2.5pp | -1.6%+3.8pp | -2.7%+1.1pp | 3.5%+7.6pp | -3.8%+2.7pp | -5.3%-0.3pp | -3.8%+6.0pp |
| Current Ratio | 5.69-0.1x | 5.90+0.5x | 4.46-0.5x | 4.48-0.4x | 5.84+0.6x | 5.37+0.2x | 4.97+0.3x | 4.90-0.5x |
| Debt-to-Equity | 0.250.0x | 0.250.0x | 0.310.0x | 0.310.0x | 0.270.0x | 0.280.0x | 0.290.0x | 0.300.0x |
| Asset Turnover | 0.150.0x | 0.150.0x | 0.160.0x | 0.140.0x | 0.180.0x | 0.170.0x | 0.180.0x | 0.160.0x |
| FCF Margin | 10.2%+0.9pp | 16.3%-4.7pp | 23.5%+29.2pp | 28.5%+16.8pp | 9.3%+6.3pp | 21.0%+34.2pp | -5.7%-17.9pp | 11.7%+38.1pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| 10x Genomics, Inc. TXG | FY2025 | $642.8M | -$43.5M | -6.8% | $10.5B | 72/100 |
| Certara, Inc. CERT | FY2025 | $418.8M | -$1.6M | -0.4% | $1.4B | 51/100 |
| Omnicell Inc OMCL | FY2025 | $1.2B | $2.1M | 0.2% | $1.6B | 42/100 |
| Phreesia, Inc. PHR | FY2026 | $480.6M | $2.3M | 0.5% | $671.0M | 45/100 |
| Schrodinger, Inc. SDGR | FY2025 | $255.9M | -$103.3M | -40.4% | $2.0B | 60/100 |
| GoodRx Holdings, Inc. GDRX | FY2025 | $796.9M | $30.4M | 3.8% | $1.2B | 56/100 |
Where 10x Genomics, Inc. Ranks
Frequently Asked Questions
What is 10x Genomics, Inc.'s annual revenue?
10x Genomics, Inc. (TXG) reported $642.8M in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 10x Genomics, Inc.'s revenue growing?
10x Genomics, Inc. (TXG) revenue grew by 5.2% year-over-year, from $610.8M to $642.8M in fiscal year 2025.
Is 10x Genomics, Inc. profitable?
No, 10x Genomics, Inc. (TXG) reported a net income of -$43.5M in fiscal year 2025, with a net profit margin of -6.8%.
What is 10x Genomics, Inc.'s EBITDA?
10x Genomics, Inc. (TXG) had EBITDA of -$24.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is 10x Genomics, Inc.'s gross margin?
10x Genomics, Inc. (TXG) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is 10x Genomics, Inc.'s operating margin?
10x Genomics, Inc. (TXG) had an operating margin of -9.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is 10x Genomics, Inc.'s net profit margin?
10x Genomics, Inc. (TXG) had a net profit margin of -6.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is 10x Genomics, Inc.'s return on equity (ROE)?
10x Genomics, Inc. (TXG) has a return on equity of -5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is 10x Genomics, Inc.'s free cash flow?
10x Genomics, Inc. (TXG) generated $130.1M in free cash flow during fiscal year 2025. This represents a 2371.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is 10x Genomics, Inc.'s operating cash flow?
10x Genomics, Inc. (TXG) generated $136.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are 10x Genomics, Inc.'s total assets?
10x Genomics, Inc. (TXG) had $1.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are 10x Genomics, Inc.'s capital expenditures?
10x Genomics, Inc. (TXG) invested $5.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does 10x Genomics, Inc. spend on research and development?
10x Genomics, Inc. (TXG) invested $238.6M in research and development during fiscal year 2025.
What is 10x Genomics, Inc.'s current ratio?
10x Genomics, Inc. (TXG) had a current ratio of 4.46 as of fiscal year 2025, which is generally considered healthy.
What is 10x Genomics, Inc.'s debt-to-equity ratio?
10x Genomics, Inc. (TXG) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 10x Genomics, Inc.'s return on assets (ROA)?
10x Genomics, Inc. (TXG) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 10x Genomics, Inc.'s P/E ratio?
10x Genomics, Inc. (TXG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $10.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is 10x Genomics, Inc.'s price-to-sales ratio?
10x Genomics, Inc. (TXG) trades at 17.0x sales, its market capitalization divided by revenue of $616.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $10.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is 10x Genomics, Inc.'s Altman Z-Score?
10x Genomics, Inc. (TXG) has an Altman Z-Score of 24.73, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is 10x Genomics, Inc.'s Piotroski F-Score?
10x Genomics, Inc. (TXG) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 10x Genomics, Inc.'s earnings high quality?
10x Genomics, Inc. (TXG) reported a net loss of $43.5M while generating $136.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is 10x Genomics, Inc.?
10x Genomics, Inc. (TXG) scores 72 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.